[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,128,632
  • Shares Outstanding, K 133,513
  • Annual Sales, $ 3,714 M
  • Annual Income, $ 313,750 K
  • EBIT $ 752 M
  • EBITDA $ 808 M
  • 60-Month Beta 0.29
  • Price/Sales 10.16
  • Price/Cash Flow 101.11
  • Price/Book 35.10

Options Overview Details

View History
  • Implied Volatility 46.79% (+1.37%)
  • Historical Volatility 31.90%
  • IV Percentile 74%
  • IV Rank 68.24%
  • IV High 54.81% on 01/09/26
  • IV Low 29.56% on 08/13/25
  • Expected Move (DTE 28) 24.35 (8.76%)
  • Put/Call Vol Ratio 0.98
  • Today's Volume 1,343
  • Volume Avg (30-Day) 647
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 27,173
  • Open Int (30-Day) 24,770
  • Expected Range 253.74 to 302.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.51
  • Number of Estimates 8
  • High Estimate $1.91
  • Low Estimate $1.00
  • Prior Year $-0.52
  • Growth Rate Est. (year over year) +390.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
273.11 +1.82%
on 06/18/26
310.53 -10.45%
on 06/04/26
-8.18 (-2.86%)
since 05/18/26
3-Month
273.11 +1.82%
on 06/18/26
343.36 -19.01%
on 04/14/26
-36.71 (-11.66%)
since 03/18/26
52-Week
273.11 +1.82%
on 06/18/26
495.55 -43.88%
on 10/20/25
-34.23 (-10.96%)
since 06/18/25

Most Recent Stories

More News
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10 th series of “RNAi Roundtable” webinars over...

ALNY : 278.09 (-1.64%)
Stocks Rebound on Strength in Banks and Managed Healthcare

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.41%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +1.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.53%. June E-mini...

PVH : 77.07 (+0.85%)
SNDK : 2,184.75 (+11.54%)
ADI : 434.46 (+4.83%)
BF.B : 26.64 (+4.43%)
ELV : 388.50 (-0.71%)
CIEN : 428.22 (-1.95%)
FIVE : 194.06 (+1.46%)
WDC : 746.23 (+4.79%)
AMD : 537.37 (+4.86%)
MDT : 79.34 (+1.54%)
SPY : 746.74 (+1.04%)
MS : 223.17 (-0.80%)
Stocks Mixed as Tech Weakness Weighs

The S&P 500 Index ($SPX ) (SPY ) today is up +0.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.90%. June E-mini S&P futures (ESM26...

CVS : 98.32 (-0.85%)
AVGO : 411.35 (+4.70%)
PVH : 77.07 (+0.85%)
SNDK : 2,184.75 (+11.54%)
ADI : 434.46 (+4.83%)
GLXY : 34.20 (+3.51%)
BF.B : 26.64 (+4.43%)
$IUXX : 30,406.19 (unch)
COIN : 163.26 (-1.00%)
UNH : 400.96 (+0.36%)
ELV : 388.50 (-0.71%)
ZNU26 : 109-105 (-0.27%)
Weakness in Technology Stocks Pressures Stock Indexes

The S&P 500 Index ($SPX ) (SPY ) today is down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.41%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.23%. June E-mini S&P futures (ESM26...

AMAT : 617.11 (+4.08%)
CVS : 98.32 (-0.85%)
AVGO : 411.35 (+4.70%)
PVH : 77.07 (+0.85%)
ADI : 434.46 (+4.83%)
GLXY : 34.20 (+3.51%)
BF.B : 26.64 (+4.43%)
$IUXX : 30,406.19 (unch)
COIN : 163.26 (-1.00%)
UNH : 400.96 (+0.36%)
ELV : 388.50 (-0.71%)
ASML : 1,929.68 (+3.31%)
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics

− Collaboration is valued at up to $2B with upfront consideration of $30M − − Alliance pairs Alnylam’s RNAi platform and 20+ years of proprietary data with Inceptive’s...

ALNY : 278.09 (-1.64%)
Alnylam Issues 2025 Corporate Responsibility Report

– Published Scope 1 and Scope 2 Greenhouse Gas (GHG) Emissions Reduction Framework through 2030 – – Expanded Global Patient Access and Support –

ALNY : 278.09 (-1.64%)
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing...

ALNY : 278.09 (-1.64%)
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies – ...

ALNY : 278.09 (-1.64%)
Alnylam to Webcast Presentations at Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:...

ALNY : 278.09 (-1.64%)
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam Pharmaceuticals, Inc . (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type...

ALNY : 278.09 (-1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 292.88
2nd Resistance Point 287.93
1st Resistance Point 283.01
Last Price 278.09
1st Support Level 273.14
2nd Support Level 268.19
3rd Support Level 263.27

See More

52-Week High 495.55
Fibonacci 61.8% 410.58
Fibonacci 50% 384.33
Fibonacci 38.2% 358.08
Last Price 278.09
52-Week Low 273.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.